- Home
- EYPT vs TRIP Comparison
EYPT vs TRIP Comparison
Compare EYPT & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | TRIP |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Computer Software: Programming Data Processing |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EYPT | TRIP |
|---|---|---|
| Price | $13.97 | $14.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | ★ $31.80 | $14.40 |
| AVG Volume (30 Days) | 1.4M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 675.00 |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $1,556,000,000.00 |
| Revenue This Year | N/A | $3.33 |
| Revenue Next Year | $3,115.57 | $5.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $9.01 |
| 52 Week High | $19.11 | $20.16 |
Technical Indicators
Market Signals| Indicator | EYPT | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 71.12 |
| Support Level | $12.01 | $13.11 |
| Resistance Level | $14.52 | $15.37 |
| Average True Range (ATR) | 1.05 | 0.74 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 51.38 | 97.69 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.